Mounjaro's China insurance listing cut Lilly's international prices 36% while volume rose 113%
Lilly's China insurance deal traded lower prices for higher volume, while what US patients pay is shaped by separate programs, including new Medicare obesity coverage.
Mounjaro (tirzepatide) joined China's National Reimbursement Drug List on January 1, 2026 [1]. Eli Lilly's second-quarter results, published August 5, show the bargain that followed: much lower prices collected abroad, and far more medicine sold [2].
Quarterly revenue came in at $22.97 billion, with adjusted earnings of $8.38 per share. Analysts surveyed by LSEG had forecast $20.73 billion and $6.01 [2]. Mounjaro generated $9.94 billion worldwide, a 91% increase, including $4.8 billion in the US. Its sales outside the US jumped 172% [2].
Companywide, revenue from outside the US reached $8.6 billion, up 80% from a year earlier. Volume rose 113%. Prices actually collected fell 36%, and Lilly tied most of that drop to the drug's inclusion in China's state-run insurance coverage for type 2 diabetes [2]. China revenue grew 93% at constant currency, driven by Mounjaro uptake [3].
CEO Dave Ricks said the international performance beat both the company's and Wall Street's expectations for "Mounjaro global adoption." He said most patients in large middle-income countries such as Brazil, China and India pay out of pocket, and that Lilly is "seeing very strong and durable demand" there [2].
The pricing shift was anticipated. A Morgan Stanley note published in May described the reimbursement listing as creating near-term price pressure while possibly supporting stronger volume later in 2026 [1]. That analysis also said generic semaglutide in China appeared delayed into 2026 for type 2 diabetes, with an obesity version potentially arriving later, based on disclosures from Jiuyuan Gene and Livzon Pharma Group [1].
Elsewhere, competition has not stalled the drug. In India, where generic semaglutide has already launched, Mounjaro still grew about 10%, which Morgan Stanley called a "halo effect" as overall category awareness expanded [1]. The same note said the medicine is sold in more than 55 countries and holds roughly 53% of the international incretin market [1]. Lilly put its global incretin share at about 55% for the quarter and said Mounjaro is now reimbursed for both type 2 diabetes and obesity in France [3].
Lilly raised its 2026 revenue outlook to $85 billion to $87 billion, from $82 billion to $85 billion [2][3].
Why it matters for patients
The discount in China came out of a negotiation with that government, and nothing in these reports says it changes US list prices or what American insurers cover [1][2]. US pricing has been moving on its own. Lilly said US prices for its medicines fell 3% in the quarter, or 9% when adjustments to rebate and discount estimates are excluded, driven by Zepbound and Mounjaro [3]. CNBC reported that Zepbound's realized prices fell partly because of previously announced cash-pay discounts [2].
How people pay still shapes access. Self-pay accounted for about 45% of Zepbound prescriptions in the quarter and about 55% of new ones [3]. Medicare's new obesity drug coverage began in early July 2026, giving eligible seniors branded GLP-1s for a $50 monthly copay [2]. Lilly says the program covers 20 million eligible Americans and reaches 35% more people in the US [3], and Ricks called the rollout "off to a strong start" [2]. He said in late April that he expects global GLP-1 use to grow from roughly 20 million patients at the end of last year to 30 million by the end of 2026 [2].
What happens next
- Timing for generic semaglutide in China, first for type 2 diabetes and later for obesity, has been reported as delayed but is not fixed [1].
- Morgan Stanley said reimbursement expansion plus delayed generic competition could make China a meaningful volume driver in the second half of 2026 [1].
- Foundayo (orforglipron), Lilly's oral GLP-1, recorded $98 million in US sales in its first quarter on the market, just below the nearly $103 million analysts expected [2]. One account places its FDA approval in the first quarter of 2026 [1]; another dates it to April [2]. The pill is under review in more than 40 countries, with a global rollout expected in 2027 [3].
Whether the China agreement affects US patient costs has not been reported.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.